What this pathway means
China has active clinical research and publicly reported clinical-application pathways involving cell-based treatment for knee osteoarthritis. The term “stem cell injection” is often used broadly, but a credible pathway should identify the cell product, treating institution, route, dose, eligibility criteria and follow-up.
For an international patient, the decision should begin with the knee diagnosis and stage. Pain can arise from cartilage loss, meniscal injury, malalignment, inflammatory disease, referred pain or advanced joint destruction. A cell-based option may be inappropriate when the main problem requires another orthopaedic strategy.
Who may be appropriate for review
Initial review is not the same as eligibility. The treating institution may consider the following factors together:
- A specialist-confirmed diagnosis of knee osteoarthritis
- Recent weight-bearing radiographs and/or MRI
- Persistent symptoms despite an appropriate period of conservative care
- A joint stage within the institution’s eligibility range
- Ability to participate in rehabilitation and follow-up
- Realistic goals such as symptom or function improvement rather than guaranteed cartilage restoration
Disease severity, comorbidities, prior treatment, realistic goals and ability to complete follow-up can all affect the decision.
Who may not be eligible
Common reasons a pathway may be unsuitable or require further specialist assessment include:
- Severe deformity or end-stage disease better suited to joint replacement
- Active joint or systemic infection
- Uncontrolled inflammatory arthritis without specialist management
- Recent major trauma or an alternative untreated structural diagnosis
- Severe medical comorbidity affecting procedural safety
- Inability to complete rehabilitation or outcome follow-up
These are general screening considerations, not a definitive exclusion list. The treating institution makes the final decision.
Medical records needed
A useful review requires more than a diagnosis name. Please prepare the most recent and clinically relevant records:
- Orthopaedic or rheumatology diagnosis
- Weight-bearing knee X-rays with date and report
- MRI report and image files if available
- Pain duration, location and functional limitation
- Prior physiotherapy, injections, medications and surgery
- Height, weight and relevant metabolic conditions
- History of inflammatory arthritis, infection or malignancy
- Current walking ability, work demands and treatment goals
Do not send unnecessary sensitive documents at first contact
Begin with a case summary. Passport copies, complete imaging archives and other sensitive files should only be transmitted through an agreed secure route after preliminary screening.
Review and treatment pathway
- Submit a case summary and recent imaging details
- Orthopaedic pre-screening identifies disease stage and missing records
- The institution reviews imaging, symptoms and prior treatment
- Further examination or imaging may be requested in China
- If accepted, a formal plan, consent discussion and quotation are provided
- Procedure, rehabilitation and follow-up are scheduled
The sequence can change after medical review. Do not book flights or make treatment payments until the institution has issued a written plan.
Evidence, uncertainty and limitations
Clinical studies of cell-based approaches for knee osteoarthritis have reported variable results. Differences in cell source, processing, dose, patient selection, comparison group, rehabilitation and outcome measures make simple claims unreliable.
Patients should ask whether the goal is pain relief, functional improvement, reduced inflammation or structural change. A claim of complete cartilage regrowth should be supported by rigorous evidence and should not be inferred from a single MRI image or testimonial.
Risks and safety questions
No cell-based or regenerative procedure is risk-free. The risk profile depends on the product, collection procedure, route of administration, patient health and follow-up.
- Injection-site pain, swelling or short-term symptom flare
- Infection or bleeding
- Procedure-related injury
- Failure to improve or temporary improvement only
- Delay of a more appropriate orthopaedic treatment
- Unknown long-term effects for some products or protocols
Patients should receive institution-specific informed-consent information before deciding.
Cost structure
Cost varies by the exact product, one or both knees, diagnostics, hospital setting, rehabilitation and follow-up. A published figure for one institution should not be assumed to apply to another protocol or to an international patient.
| Cost component | What to confirm |
|---|---|
| Hospital medical fee | Procedure, cell product, hospital stay and direct clinical care |
| Pre-treatment diagnostics | Tests required before eligibility or treatment |
| Specialist consultation | Remote review, MDT or in-person consultation |
| International coordination | Case preparation, scheduling, language and patient support |
| Travel and accommodation | Flights, hotels, local transport and non-medical expenses |
A formal medical quotation should follow record review. We do not present an unverified package price as a substitute for a hospital plan.
International patient timeline
Record review can begin remotely. The visit may include orthopaedic examination, updated imaging or laboratory tests, the procedure and a rehabilitation plan. Travel timing should allow for post-procedure observation and clear instructions for return-home care.
Travel duration depends on the review outcome, tests, procedure schedule and follow-up requirements. Patients should keep enough flexibility for additional assessment.